carbitol has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kohli, K; Mangla, B; Neupane, YR; Singh, A; Sonali, LJ; Soni, NK | 1 |
| Datta, D; Dave, KM; Gayen, JR; Gupta, AP; Mitra, K; Riyazuddin, M; Singh, A; Syed, AA; Valicherla, GR | 1 |
2 other study(ies) available for carbitol and Breast Neoplasms
| Article | Year |
|---|---|
Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Drug Carriers; Ethylene Glycols; Fatty Acids; Female; Humans; MCF-7 Cells; Nanostructures; Raloxifene Hydrochloride; Rats, Wistar; Selective Estrogen Receptor Modulators | 2020 |
Formulation optimization of Docetaxel loaded self-emulsifying drug delivery system to enhance bioavailability and anti-tumor activity.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Survival; Docetaxel; Drug Compounding; Drug Delivery Systems; Drug Stability; Emulsions; Ethylene Glycols; Female; Humans; Male; MCF-7 Cells; Mice, Inbred BALB C; Polyethylene Glycols; Polymers; Propylene Glycols; Rats; Rats, Sprague-Dawley; Solubility; Taxoids; Vitamin E; Xenograft Model Antitumor Assays | 2016 |